Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Welcome and Introduction to Vi3C

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Apr
21
Today In Oncology
Metastatic NSCLC Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
Methylation-Based AI Model Classifies Tumors of Unknown Origin
Initial Data Shows Safety for WEE1 PKMYT1 Inhibitor Combination in Advanced Solid Tumors
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo